LIMN

Conviction 0HealthcareScan · Mon, Aug 10, 2026

Three outside up

LIMN$0.1213+17.77%

ResistanceSupportVol 14

Vol MA14 4.19M

May 11May 28Jun 16Jul 6Jul 23Aug 10

Liminatus Pharma, Inc.Biological Products, (No Diagnostic Substances)liminatuspharma.com ↗

Price0.1213

Change+17.77%

Gap+0.19%

Rel volume0.00×

Avg volume39.45M

Avg $ vol5.48M

SMA 200.1126

SMA 500.1226

SMA 2000.4776

Price vs 50-1.04%

Price vs 200-74.60%

MA stackbearish

50/200 cross—

Supertrendup · 0.0945

RSI (14)53

MACD hist0.00

MACD crossbull · 5d

Stoch %K / %D79 / 37

ADX (14)22

+DI / −DI33 / 19

RSI divergence—

MACD divergence—

ATR %+14.07%

ADR %13.50%

52w high4.48

52w low0.0989

From 52w high-97.29%

Above 52w low+22.65%

New 52w highNo

SqueezeOn · 27d

Bollinger width39.42%

%B0.70

Donchian pos25.89%

Donchian high0.1960

Donchian low0.0952

AVWAP (52w high)0.4686

vs AVWAP high-74.12%

AVWAP (52w low)0.1474

vs AVWAP low-17.69%

OBV trendUp

Chaikin MF (20)-0.36

Today vs 20d0.00×

Avg vol (14d)4.19M

Avg vol (20d)39.45M

Avg $ vol (20d)5.48M

Market cap5.44M

RS 3m (vs SPY)-54.33%

RS 6m (vs SPY)-109.09%

RS line new highNo

Trend template0/8

Technical rank25.4

1 week+6.68%

1 month+6.03%

3 months-40.19%

6 months-93.41%

1 year-97.49%

YTD-81.07%

P/E-0.53

P/B-41.05

P/S—

P/FCF-0.55

EPS-0.4300

Div yield—

ROE—

ROA-365.79%

Debt/Eq-10.88

Current0.96

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-187.81%

Price target—

Target upside—

Analyst rating—

Institutional2.28%

Ent. value6.89M

Revenue—

Net income-1.12M

Gross profit—

Free cash flow-9.98M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out44.88M

Employees1

ListedThu, May 1, 2025

Free float33.49M

Float %74.6%

Short interest2.4M

Days to cover0.0d

Short volume59.8%

Squeeze score28 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank25.4 / 100

Group rank—

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmThree outside up

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LIMN

All disclosures →

No recent disclosed trades by Congress in LIMN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LIMN

No recent insider (Form 4) filings in LIMN. Insiders must file within two business days of a trade.

SEC filings

EDGAR filings in LIMN · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.